Stay updated with breaking news from Vectivbio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
VectivBio (NASDAQ:VECT – Get Rating) was downgraded by analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating in a report released on Monday, The Fly reports. Separately, Piper Sandler boosted their price target on VectivBio from $23.00 to $25.00 and gave the company an “overweight” rating in a research note on […] ....
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of VectivBio Holding AG to Ironwood Pharmaceuticals, Inc. for $17.00 per share is fair to VectivBio. | May 22, 2023 ....
-Ironwood Pharmaceuticals Inc said on Monday it would buy Switzerland-based drug developer VectivBio Holding AG for $1.15 billion, adding a promising treatment for digestive disorders to its. | May 22, 2023 ....
GI-focused healthcare company Ironwood Pharmaceuticals, Inc. (IRWD) and biopharmaceutical company VectivBio Holding AG (VECT) announced Monday that they have entered into a definitive agreement for Ironwood to acquire VectivBio for $17. ....
BASEL, Switzerland, May 10, 2023 VectivBio Holding AG , a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the. | May 10, 2023 ....